CN113543781A - 通过控制峰值血浆水平使用多西他赛的癌症治疗 - Google Patents

通过控制峰值血浆水平使用多西他赛的癌症治疗 Download PDF

Info

Publication number
CN113543781A
CN113543781A CN201980090615.9A CN201980090615A CN113543781A CN 113543781 A CN113543781 A CN 113543781A CN 201980090615 A CN201980090615 A CN 201980090615A CN 113543781 A CN113543781 A CN 113543781A
Authority
CN
China
Prior art keywords
docetaxel
cancer
administered
treatment
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090615.9A
Other languages
English (en)
Chinese (zh)
Inventor
雅克布·昂德里克·拜占恩
乔纳斯·亨里克斯·马提亚·舍伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modra Pharmaceuticals BV
Original Assignee
Modra Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modra Pharmaceuticals BV filed Critical Modra Pharmaceuticals BV
Publication of CN113543781A publication Critical patent/CN113543781A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980090615.9A 2018-12-21 2019-12-18 通过控制峰值血浆水平使用多西他赛的癌症治疗 Pending CN113543781A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215472 2018-12-21
EP18215472.4 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Publications (1)

Publication Number Publication Date
CN113543781A true CN113543781A (zh) 2021-10-22

Family

ID=64901394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090615.9A Pending CN113543781A (zh) 2018-12-21 2019-12-18 通过控制峰值血浆水平使用多西他赛的癌症治疗

Country Status (14)

Country Link
US (3) US20220079910A1 (https=)
EP (2) EP3897610B1 (https=)
JP (3) JP2022515249A (https=)
KR (1) KR20220002860A (https=)
CN (1) CN113543781A (https=)
AU (2) AU2019410060A1 (https=)
BR (1) BR112021012255A2 (https=)
CA (1) CA3124316C (https=)
CL (1) CL2021001638A1 (https=)
ES (1) ES3026709T3 (https=)
IL (1) IL284213A (https=)
MX (2) MX2021007478A (https=)
PE (1) PE20220250A1 (https=)
WO (1) WO2020127606A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027644A2 (en) * 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
JP2012500788A (ja) 2008-08-22 2012-01-12 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物
PE20220250A1 (es) * 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027644A2 (en) * 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE WEGER V A等: "A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir", 《EUROPEAN JOURNAL OF CANCER》, vol. 86, 12 October 2017 (2017-10-12), pages 217 - 225, XP085280689, DOI: 10.1016/j.ejca.2017.09.010 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113473982A (zh) * 2018-12-21 2021-10-01 莫德拉药物股份有限责任公司 使用多西他赛和cyp3a抑制剂组合治疗实体瘤

Also Published As

Publication number Publication date
EP4670718A2 (en) 2025-12-31
CA3124316A1 (en) 2020-06-25
JP2022515249A (ja) 2022-02-17
BR112021012255A2 (pt) 2021-09-28
CL2021001638A1 (es) 2022-04-22
IL284213A (en) 2021-08-31
JP2023102787A (ja) 2023-07-25
AU2019410060A1 (en) 2021-08-05
MX2025008270A (es) 2025-08-01
EP4670718A3 (en) 2026-03-04
US20220323399A1 (en) 2022-10-13
US20220079910A1 (en) 2022-03-17
EP3897610C0 (en) 2025-04-16
AU2023204682A1 (en) 2023-08-10
CA3124316C (en) 2023-07-04
EP3897610B1 (en) 2025-04-16
KR20220002860A (ko) 2022-01-07
EP3897610A1 (en) 2021-10-27
JP2025094189A (ja) 2025-06-24
ES3026709T3 (en) 2025-06-12
PE20220250A1 (es) 2022-02-16
US20250312305A1 (en) 2025-10-09
MX2021007478A (es) 2021-10-13
WO2020127606A1 (en) 2020-06-25
US11571408B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
TW202110434A (zh) 用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸
JP2023102786A (ja) ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
CN114177299A (zh) 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
US20260027117A1 (en) Methods of treating small cell lung cancer
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2021228146A1 (zh) 一种lsd1抑制剂的用途
CN101185652B (zh) 肺癌治疗药
CN115038447A (zh) 用于治疗癌症的组合疗法
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
WO2019129168A1 (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途
CN118946350A (zh) 用于治疗紫杉烷耐药性患者的癌症的方法和组合物
US20220409611A1 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination